5-(N,N-二苄基氨基乙酰)水杨酰胺 | 30566-92-8

• 物质功能分类: 有机原料 - 氨基化合物 - 酰胺类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 5-(N,N-二苄基氨基乙酰)水杨酰胺
• 中文别名: 5-(N,N-二苄氨基乙酰)水杨酰胺；5-((2-二苄胺基)-乙酰基)-水杨酰胺；5-N,N-二苄胺乙酰水杨酰胺
• 英文名称: 5-(N,N-dibenzylamino)acetylsalicylamide
• 英文别名: 2-Carbamoyl-4-[2-(dibenzylazaniumyl)acetyl]phenolate
• CAS: 30566-92-8
• 化学式: C₂₃H₂₂N₂O₃
• 分子量: 374.439
• InChiKey: DNLPQXRWAKCKPX-UHFFFAOYSA-N

物化性质

• 熔点：
  168 °C
• 沸点：
  503.44°C (rough estimate)
• 密度：
  1.2085 (rough estimate)
• 稳定性/保质期：
  遵照规定使用和储存，则不会发生分解。

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2924299090
• 安全说明：
  S24/25
• 储存条件：
  存储于阴凉干燥处即可。

SDS

Name:	5-(N N-Dibenzylglycyl)salicylamide 98% Material Safety Data Sheet
Synonym:	None Known
CAS:	30566-92-8

Section 1 - Chemical Product MSDS Name:5-(N N-Dibenzylglycyl)salicylamide 98% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
30566-92-8	5-(N,N-Dibenzylglycyl)salicylamide	98%	250-244-9

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid.
Skin:
In case of contact, flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical aid if irritation develops and persists. Wash clothing before reuse.
Ingestion:
If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 30566-92-8: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: light beige
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 168 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C23H22N2O3
Molecular Weight: 374.44

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Strong oxidizing agents, acids, acid chlorides, acid anhydrides, carbon dioxide.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 30566-92-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-(N,N-Dibenzylglycyl)salicylamide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 30566-92-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 30566-92-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 30566-92-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途
用作心血管药物拉贝诺尔（柳胺苄心定）的中间体，以及通用的有机中间体。

反应信息

• 作为反应物：
  描述：

  5-(N,N-二苄基氨基乙酰)水杨酰胺 在 palladium on activated charcoal 、 platinum on activated charcoal 氢气 、 potassium carbonate 作用下， 以 乙醇 、 丁酮 为溶剂， 生成 2-(2-Ethoxyethoxy)-5-[2-[(1-ethyl-3-phenylpropyl)amino]-1-hydroxyethyl]benzamide
  参考文献：
  名称：

  FR2228487

  摘要：

  公开号：
• 作为产物：
  描述：

  水杨酰胺 在 aluminum (III) chloride 、 对甲苯磺酸 、 三乙胺 、 potassium iodide 作用下， 以 四氢呋喃 、 硝基甲烷 、 甲苯 为溶剂， 生成 5-(N,N-二苄基氨基乙酰)水杨酰胺
  参考文献：
  名称：

  一种5-N,N-二苄胺乙酰水杨酰胺的合成方法

  摘要：

  本发明公开了一种5‑N,N‑二苄胺乙酰水杨酰胺的合成方法。该合成方法是首先将水杨酰胺用不同取代基的醛、酮或缩醛、缩酮保护得到中间体I，然后与α‑卤代酰化试剂反应得到中间体II，再由二苄胺取代卤原子，最后酸化脱保护得到5‑N,N‑二苄胺乙酰水杨酰胺。本发明提供的合成方法，具有收率高，杂质少，成本低，且易于放大等特点。

  公开号：

  CN109369556A
• 作为试剂：
  描述：

  5-(N, N-dibenzylglycyl)-2-(octyloxy)benzamide 以 5-(N,N-二苄基氨基乙酰)水杨酰胺 为溶剂， 以51%的产率得到5-[1-Hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]-2-(octyloxy)benzamide, hydrochloride
  参考文献：
  名称：

  Pharmacologically active compounds

  摘要：

  化合物的公式为##STR1## 其中：R.sub.4和R.sub.5独立地表示氢或较低的烷基；R.sub.6表示一个Y(CH.sub.2).sub.n基团，其中n为2或3，Y表示一种直链或支链烷基，包含5个碳原子，可选地被一个或多个羟基或烷氧基取代，或者被含有羟基或烷氧基取代的芳基取代，该芳基本身也可以含有一个或多个羟基或烷氧基取代；或者Y表示一个ZO--基团，其中Z表示一种直链或支链烷基，含有2至6个碳原子，可被一个或多个烷氧基，羟基或芳氧基取代；或者Z表示一个芳基，该芳基可选择地含有一个或多个羟基或烷氧基取代；R.sub.7表示一种含有3至6个碳原子的直链或支链烷基，可选择地被一个芳基或芳氧基取代，该芳基或芳氧基本身也可以被羟基和烷氧基取代。以及其药学上可接受的盐。这些化合物在心血管疾病的治疗中具有实用价值。

  公开号：

  US04000192A1

文献信息

• Arylethanolamines derived from salicylamide with .alpha.- and .beta.-adrenoceptor blocking activities. Preparation of labetalol, its enantiomers and related salicylamides
  作者：James E. Clifton、Ian Collins、Peter Hallett、David Hartley、Lawrence H. C. Lunts、Philip D. Wicks

  DOI：10.1021/jm00348a013

  日期：1982.6

  A series of phenethanolamines (3) based on salicylamide has been prepared and shown to possess beta-adrenergic blocking properties. When the basic nitrogen atom was substituted by some aralkyl groups, the compounds also blocked alpha-adrenoceptors. The 1-methyl-3-phenylpropyl derivative labetalol (34) is antihypertensive in animals and man, and syntheses of its four stereoisomers are described. The

  已经制备了一系列基于水杨酰胺的苯乙醇胺（3），并显示出具有β-肾上腺素阻断特性。当碱性氮原子被某些芳烷基取代时，这些化合物也会封闭α-肾上腺素受体。1-甲基-3-苯基丙基衍生物拉贝洛尔（34）在动物和人类中均具有降压作用，并描述了其四种立体异构体的合成。在两个不对称中心具有R构型的对映体90具有大部分的β-阻断活性，但是几乎没有α-阻断活性。在醇碳上具有S构型并且在氨基取代基上具有R构型的化合物主要是α-肾上腺素受体阻断剂89。
• Phenethanolamine ethers
  申请人：Allen & Hanburys Limited

  公开号：US04101579A1

  公开（公告）日：1978-07-18

  Compounds of the general formula I and physiologically acceptable acid addition salts thereof:- ##STR1## in which R.sup.1 is a lower alkyl, lower alkenyl, or arylalkyl radical, which radicals may optionally be substituted by one or more alkoxy or hydroxy groups. R.sup.2 represents a hydrogen atom or a lower alkyl radical which may optionally be substituted by one or more hydroxy groups, amino groups, or heterocyclic rings containing one or more heteroatoms, or R.sup.2 represents a cycloalkyl, arylalkyl or aryloxyalkyl radical, which radicals may optionally be substituted by one or more alkoxy or hydroxy groups; R.sup.3 represents a hydrogen atom or a benzyl group; X represents a group of formula --CONR.sup.4 R.sup.5 where R.sup.4 and R.sup.5 may be the same or different and each represents hydrogen or a lower alkyl group; With the proviso that when R.sup.2 is tertiary butyl and R.sup.1 is a benzyl group, R.sup.3 represents a hydrogen atom. The compounds have a blocking action on .beta.-adrenergic receptors and in some cases an antagonising effect on .alpha.-adrenergic receptors.

  通式I和其生理学上可接受的酸盐包括以下化合物：- ##STR1## 其中R.sup.1是较低的烷基、较低的烯基或芳基烷基基团，这些基团可能被一个或多个烷氧基或羟基取代。R.sup.2代表氢原子或一个较低的烷基基团，该基团可能被一个或多个羟基、氨基或含有一个或多个杂原子的杂环的环取代，或者R.sup.2代表一个环烷基、芳基烷基或芳氧基烷基基团，这些基团可能被一个或多个烷氧基或羟基取代；R.sup.3代表氢原子或苄基；X代表一个公式--CONR.sup.4 R.sup.5的基团，其中R.sup.4和R.sup.5可以相同也可以不同，每个代表氢或较低的烷基基团；但有一个条件，即当R.sup.2是叔丁基且R.sup.1是苄基时，R.sup.3代表氢原子。这些化合物对β-肾上腺素受体具有阻断作用，并在某些情况下对α-肾上腺素受体具有拮抗作用。
• Arylmethoxy-, arylmethylthio-, heteroarylmethoxy-, and
  申请人：Schering Corporation

  公开号：US04379166A1

  公开（公告）日：1983-04-05

  This invention relates to 5-(2-alkylamino-1-hydroxyethyl)salicylamides and 4-(2-alkylamino-1-hydroxyethyl)-2-(methylsulfinyl)phenols wherein the alkyl group is substituted by arylmethoxy, arylmethylthio, heteroarylmethoxy, or heteroarylmethylthio, pharmaceutical compositions thereof, and their use as cardiovascular agents.

  本发明涉及5-(2-烷基氨基-1-羟乙基)水杨酰胺和4-(2-烷基氨基-1-羟乙基)-2-(甲基亚磺酰基)苯酚，其中烷基基团被芳基甲氧基、芳基甲硫基、杂芳基甲氧基或杂芳基甲硫基取代，以及其制备的药物组合物，并用作心血管药物。
• 一种5-(N,N-二苄基氨基)乙酰水杨酰胺的制 备方法
  申请人：上海应用技术学院

  公开号：CN104513177B

  公开（公告）日：2017-01-04

  本发明一种5‑(N,N‑二苄基氨基)乙酰水杨酰胺的制备方法，将水杨酰胺和氯乙酰氯按照摩尔比1:2.5~5.5加入到一个容器中进行反应，用离子液体作为溶剂，离子液体和水杨酰胺的摩尔比为5‑10：1，在35‑55℃常压下反应，反应完成后用有机溶剂萃取得到产品5‑氯乙酰水杨酰胺，将制得的5‑氯乙酰水杨酰胺和二苄胺加入水和甲醇的混合液中，所述的甲醇和水的体积比为2~4:1，50~70℃加热反应2~4小时，5‑氯乙酰水杨酰胺和二苄胺摩尔比为：1:1.0~1.2，反应完成后减压蒸馏除去溶剂、重结晶得到5‑(N，N‑二苄基氨基)乙酰水杨酰胺。本发明生产成本低，合成步骤短、收率高、环境污染小。
• SHANG YUN; WANG YIJUN; FENG JUNCAI; ZHANG NANXIAN; CHEN WEIXING; GAO RUIQ+, NANTSZIN DASYUEH SYUEHBAO TSZYZHAN KEHSYUEH, NANJING DAXUE XUE BAO, J. NA+
  作者：SHANG YUN、 WANG YIJUN、 FENG JUNCAI、 ZHANG NANXIAN、 CHEN WEIXING、 GAO RUIQ+

  DOI：——

  日期：——